Pancreatic Adenocarcinoma Non-resectable Clinical Trial
Official title:
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for this disease. Dendritic cells are cells that are present in the body's immune system that help your body fight disease.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02336672 -
EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)
|
N/A | |
| Active, not recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Recruiting |
NCT05524090 -
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
|
||
| Terminated |
NCT02910882 -
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT03772756 -
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
|
N/A | |
| Completed |
NCT01053013 -
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
|
Phase 2 |